<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03643913</url>
  </required_header>
  <id_info>
    <org_study_id>NS918</org_study_id>
    <nct_id>NCT03643913</nct_id>
  </id_info>
  <brief_title>The Effect of Deep Neuromuscular Block and Reversal With Sugammadex on Surgical Conditions and Perioperative Morbidity in Shoulder Surgery Using a Deltopectoral Approach</brief_title>
  <official_title>The Effect of Deep Neuromuscular Block and Reversal With Sugammadex on Surgical Conditions and Perioperative Morbidity in Shoulder Surgery Using a Deltopectoral Approach</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MSD Belgium BVBA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study evaluates wether deep neuromuscular block during entire surgical procedure to the
      gleno-humeral joint or the proximal humerus using a deltoideo-pectoral approach results in
      less muscular damage to the deltoid muscle and therefore less post-operative pain and an
      earlier functional recovery..
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 18, 2018</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>The patient and the surgeon are blinded for the intervention. The anesthesist knows the allocation.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Modified Leiden score</measure>
    <time_frame>1 Day of surgery</time_frame>
    <description>the surgeon will be asked to score the surgical conditions on a five step scale based upon previously used scales:
grade 5: optimal surgical conditions, perfect access to the proximal humerus, glenohumeral joint and excellent visibility.
grade 4: good conditions: adequate surgical conditions to perform the surgery, but not optimal
grade 3: acceptable conditions, surgical procedure is jeopardized, but adequate surgical result is obtained, eventually after additional intervention
grade 2: poor conditions, exposure and handling hindered resulting in suboptimal surgical outcome
grade 1: extremely poor conditions, the surgeon is unable to work because of the inability to get access to the shoulder joint because of inadequate muscle relaxation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual analogue scale (VAS)</measure>
    <time_frame>Day 3 post-operative at 14 o' clock</time_frame>
    <description>Scale ranges from 0 to 10 representing respectively no pain and wordt imaginable pain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Muscular damage</measure>
    <time_frame>1 Day of surgery</time_frame>
    <description>Two light photos will be taken before closure of the deltoideopectoral interval to document the muscular damage by the surgeon using a grading score (1-4, 1=no muscular damage, 2=superficial damage (fraying) or contusion, 3=muscular tear &lt; 1 cm depth, 4=muscular tear &gt; 1 cm depth).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscular damage</measure>
    <time_frame>1 year after inclusion</time_frame>
    <description>Two light photos will be taken before closure of the deltoideopectoral interval to document the muscular damage by two independent reviewers (surgeons blinded to the procedure) using a grading score (1-4, 1=no muscular damage, 2=superficial damage (fraying) or contusion, 3=muscular tear &lt; 1 cm depth, 4=muscular tear &gt; 1 cm depth).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS</measure>
    <time_frame>The scoring will be done at 8-14 and 20 o'clock on days 1-3-5 post-operative and once a day from day 5 to day 30 post-operative.</time_frame>
    <description>Scale ranges from 0 to 10 representing respectively no pain and worst imaginable pain. Post-operative pain will be scored using a VAS-pain scale ranging from 0 (no pain) to 10 (worst imaginable pain).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analgesic needs</measure>
    <time_frame>Up to 5 days post-operative</time_frame>
    <description>The analgesic needs of the patient during hospitalization will be derived from the Electronic Medical Prescription (EMV) module of the Electronic patient file system. The total morphine consumption will be assessed in all groups as well as rescue medication such as ketalar, NSAID's catapressan and paracetamol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analgesic needs</measure>
    <time_frame>From hospital discharge to 30 days post-operative</time_frame>
    <description>The analgesic needs of the patient after hospitalization will be derived from a patient diary.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay at post-anesthesia care unit (PACU)</measure>
    <time_frame>1 Day of surgery</time_frame>
    <description>Evaluation and length of stay at the PACU will also be examined as this clearly reflects the amount of post-operative comfort or possible adverse effects witnessed post procedure. The parameter will be expressed in hours and there will be two measurement. The time of expected discharge and the actual discharge (with reasons of possible delay between those two figures expressed in minutes or hours).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of surgery</measure>
    <time_frame>intraoperative</time_frame>
    <description>Will be expressed in %. As different procedures are being performed within this study, absolute length would not be indicative for ease of procedure. Therefore we express length of surgery as actual length of the procedure (incision to closure), divided by the mean length of the 10 last identical procedures (out of the study) performed by the same surgeon.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay</measure>
    <time_frame>from day 3 up to 3 weeks after surgery</time_frame>
    <description>Is defined as post-operative length of stay, the day of surgery being day 0. This parameter will be expressed in days. As post-operative pain is one of the principal reasons for hospitalization after shoulder surgery, we believe this parameter is an indirect measure for post-operative pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of dry catheter technique</measure>
    <time_frame>1 Day of surgery</time_frame>
    <description>Evaluation of the efficacy of the catheter will be done 30 minutes after the bolus injection. Efficacy will be tested by using ether swab to test sensory block and also motorfunction evaluation of the motorjoint (raising arm to full height pass/fail).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Shoulder Pain</condition>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>Comparison group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Neuromuscular Blocking Agents and reversing agents: The comparison group will receive anesthesia top up Esmeron dose to maintain a Train Of Four (TOF) count of maximum 2 during the whole procedure. This represents moderate neuromuscular block conditions. A neuromuscular monitor (PHILIPS integrated) will be used to evaluate TOF count.
To maintain TOF at 2 and according to our practice a bolus injection of 0,1 mg/kg Rocuronium will be given when TOF count returns to 3. This dose will be repeated if TOF does not go back to 2 within 2 minutes after bolus injection. TOF guard and TOF tube will be used at the ulnar nerve at the contralateral side and will be checked continuously during surgery.
Reversal of the TOF=2 will be done by Sugammadex 2 mg/kg at end of procedure (Time of last suture)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Deep group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neuromuscular Blocking Agents and reversing agents: The deep group will receive deep neuromuscular block, using a infusion of Esmeron at 0,1mg/kg/hour. A post tetanic count will be performed and our target will be to have a PTC 1-2. The standard infusion will be adjusted as such. Reversal will be achieved by Sugammadex 4 mg/kg depending on reversal speed at the end of procedure (Time of last suture)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Deep neuromuscular block</intervention_name>
    <description>Deep neuromuscular block requiring higher doses of Esmeron to target a post tetanic count (PTC) of 1-2 and higher doses of Bridion to reverse the block (4mg/kg).</description>
    <arm_group_label>Deep group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Moderate neuromuscular block</intervention_name>
    <description>Normal neuromuscular block requiring dosis of Esmeron to target a train of four (TOF) count of max 2 and lower doses of Bridion to reverse the block (2mg/kg).</description>
    <arm_group_label>Comparison group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neuromuscular Blocking Agents and reversing agents</intervention_name>
    <description>Deep neuromuscular block versus moderate neuromuscular block.</description>
    <arm_group_label>Comparison group</arm_group_label>
    <arm_group_label>Deep group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        â€¢ Adult patient undergoing elective or semi-elective surgery to the gleno-humeral joint or
        the proximal humerus using a deltoideo-pectoral approach

        Exclusion Criteria:

          -  Inability to consent because of mental status

          -  Open injuries involving the deltoid muscle

          -  Previous open surgery on the shoulder joint.

          -  American Society of Anaesthesiologists (ASA) physical status &gt;II

          -  Age &lt;18 or &gt;75 year old

          -  Body mass index (BMI) &lt;18.5 or &gt;35 kg/m2

          -  Renal insufficiency (glomerular filtration rate &lt;40 ml/min)

          -  Impaired liver function (hepatic cirrhosis, cholestatic jaundice)

          -  Neuromuscular disease

          -  Pregnancy

          -  Breastfeeding

          -  Predicted difficult airway

          -  Patients receiving medications known to interact with neuromuscular blocking agents

          -  Allergy to any drug included in the anesthetic protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefaan Nijs, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitaire Ziekenhuizen Leuven</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ellen Nijs, MSc.</last_name>
    <phone>016 34 23 64</phone>
    <phone_ext>0032</phone_ext>
    <email>ellen.1.nijs@uzleuven.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kathleen Ceuleers</last_name>
    <phone>016 34 46 66</phone>
    <phone_ext>0032</phone_ext>
    <email>kathleen.ceuleers@uzleuven.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospitals Leuven</name>
      <address>
        <city>Leuven</city>
        <state>Vlaams-Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefaan Nijs, Prof. Dr.</last_name>
      <phone>016 34 46 65</phone>
      <phone_ext>0032</phone_ext>
      <email>stefaan.nijs@uzleuven.be</email>
    </contact>
    <investigator>
      <last_name>Steve Coppens, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arne Neyrinck, Prof. Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Willem Metsemakers, Prof. Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stefaan Nijs, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>August 6, 2018</study_first_submitted>
  <study_first_submitted_qc>August 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 23, 2018</study_first_posted>
  <last_update_submitted>November 6, 2019</last_update_submitted>
  <last_update_submitted_qc>November 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitaire Ziekenhuizen Leuven</investigator_affiliation>
    <investigator_full_name>Stefaan Nijs, prof. dr.</investigator_full_name>
    <investigator_title>Prof. Dr. Stefaan Nijs</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shoulder Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuromuscular Blocking Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

